Assetmark Inc. lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 28.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 95,028 shares of the company’s stock after acquiring an additional 21,038 shares during the period. Assetmark Inc.’s holdings in AstraZeneca were worth $5,211,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the company. Atria Investments LLC grew its position in shares of AstraZeneca by 24.1% during the third quarter. Atria Investments LLC now owns 76,823 shares of the company’s stock worth $4,213,000 after acquiring an additional 14,905 shares during the last quarter. Mitchell & Pahl Private Wealth LLC grew its position in AstraZeneca by 4.9% in the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 9,803 shares of the company’s stock valued at $538,000 after buying an additional 461 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in AstraZeneca by 7.2% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,618 shares of the company’s stock valued at $1,460,000 after buying an additional 1,782 shares in the last quarter. Optas LLC grew its position in AstraZeneca by 24.4% in the 3rd quarter. Optas LLC now owns 4,440 shares of the company’s stock valued at $242,000 after buying an additional 872 shares in the last quarter. Finally, TRU Independence Asset Management 2 LLC grew its position in AstraZeneca by 248.3% in the 3rd quarter. TRU Independence Asset Management 2 LLC now owns 13,651 shares of the company’s stock valued at $749,000 after buying an additional 9,732 shares in the last quarter. Institutional investors own 16.42% of the company’s stock.
AstraZeneca Price Performance
AZN stock opened at $71.08 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a one year low of $52.65 and a one year high of $72.12. The firm has a market capitalization of $220.27 billion, a PE ratio of 106.09, a P/E/G ratio of 1.30 and a beta of 0.53. The firm has a 50-day moving average of $67.41 and a two-hundred day moving average of $62.62.
AstraZeneca (NASDAQ:AZN – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported $0.84 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.07. AstraZeneca had a net margin of 4.52% and a return on equity of 29.40%. The company had revenue of $10.98 billion during the quarter, compared to analyst estimates of $10.98 billion. On average, analysts forecast that AstraZeneca PLC will post 3.33 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the stock. TheStreet upgraded shares of AstraZeneca from a “c” rating to an “a” rating in a research report on Monday, December 5th. Guggenheim decreased their target price on shares of AstraZeneca from £120 ($146.20) to £118 ($143.76) in a research report on Tuesday, October 11th. BMO Capital Markets began coverage on shares of AstraZeneca in a research report on Thursday, January 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. upped their price target on shares of AstraZeneca from £125 ($152.29) to £135 ($164.47) in a report on Tuesday, January 3rd. Finally, Berenberg Bank cut their price target on shares of AstraZeneca from GBX 120 ($1.46) to GBX 118 ($1.44) in a report on Wednesday, October 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Hold” and a consensus target price of $9,509.78.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.